GSK Taps Cellzome For Inflammatory Disease Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK will pay Cellzome £14.4 million upfront for options to Kinobeads drug candidates.
You may also be interested in...
Deals of the Week: GSK Working On Three Deals, Agilent/Dako
GlaxoSmithKline tries to turn partnerships into acquisitions with varying results, as one company accepts a buy-out while another adopts a poison-pill strategy.
GSK/Exelixis: The End of an Era
Six-year alliance allowed Exelixis to build a pipeline; after gaining $260 million in funding, GSK walks away with rights to only one compound.
GSK/Exelixis: The End of an Era
Six-year alliance allowed Exelixis to build a pipeline; after gaining $260 million in funding, GSK walks away with rights to only one compound.